Literature DB >> 32303830

Hypothermia in patients with acute myocardial infarction: a meta-analysis of randomized trials.

Brunilda Alushi1, Gjin Ndrepepa2, Alexander Lauten1,3, Anna Lena Lahmann2, Dario Bongiovanni4, Sebastian Kufner2, Erion Xhepa2, Karl-Ludwig Laugwitz4,5, Michael Joner2,5, Ulf Landmesser1,6,3, Holger Thiele7, Adnan Kastrati2,5, Salvatore Cassese8.   

Abstract

BACKGROUND: In patients with acute myocardial infarction (MI) receiving percutaneous coronary intervention (PCI), the role of systemic therapeutic hypothermia remains controversial. We sought to investigate the role of systemic therapeutic hypothermia versus standard of care in patients with acute MI treated with PCI.
METHODS: This is a study-level meta-analysis of randomized trials. The primary outcome was all-cause death. The main secondary outcome was infarct size. Other secondary outcomes were recurrent MI, ischemia-driven target vessel revascularization (TVR), major adverse cardiovascular events, and bleeding.
RESULTS: A total of 1012 patients with acute MI receiving a PCI in nine trials (503 randomly assigned to hypothermia and 509 to control) were available for the quantitative synthesis. The weighted median follow-up was 30 days. As compared to controls, patients assigned to hypothermia had similar risk of all-cause death (risk ratio, [95% confidence intervals], 1.25 [0.80; 1.95], p = 0.32), with a trend toward higher risk of ischemia-driven TVR (3.55 [0.80; 15.87], p = 0.09) mostly due to acute or subacute stent thrombosis. Although in the overall cohort, infarct size was comparable between groups (standardized mean difference [95% Confidence intervals], 0.06 [- 0.92; 1.04], p = 0.92), patients effectively achieving the protocol-defined target temperature in the hypothermia group had smaller infarct size as compared to controls (p for interaction = 0.016). Treatment strategies did not differ with respect to the other outcomes.
CONCLUSIONS: As compared to standard of care, systemic therapeutic hypothermia in acute MI patients treated with PCI provided similar mortality with a signal toward more frequent repeat revascularization. Among patients assigned to hypothermia, those effectively achieving the protocol-defined target temperature displayed smaller infarct size. TRIAL REGISTRATION: PROSPERO, CRD42019138754.

Entities:  

Keywords:  Hypothermia; Meta-analysis; Myocardial infarction; Percutaneous coronary intervention; Randomized trial

Year:  2020        PMID: 32303830     DOI: 10.1007/s00392-020-01652-7

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  4 in total

1.  'Ten Commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.

Authors:  Franz-Josef Neumann; Miguel Sousa-Uva
Journal:  Eur Heart J       Date:  2018-11-07       Impact factor: 29.983

2.  Selective intracoronary hypothermia in patients with ST-elevation myocardial infarction. Rationale and design of the EURO-ICE trial.

Authors:  Mohamed El Farissi; Daniëlle C J Keulards; Marcel van 't Veer; Jo M Zelis; Colin Berry; Bernard De Bruyne; Thomas Engstrøm; Ole Fröbert; Zsolt Piroth; Keith G Oldroyd; Pim A L Tonino; Nico H J Pijls; Luuk C Otterspoor
Journal:  EuroIntervention       Date:  2021-04-20       Impact factor: 6.534

3.  Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction.

Authors:  Gjin Ndrepepa; Julinda Mehilli; Markus Schwaiger; Helmut Schühlen; Stephan Nekolla; Stefan Martinoff; Claus Schmitt; Josef Dirschinger; Albert Schömig; Adnan Kastrati
Journal:  J Nucl Med       Date:  2004-05       Impact factor: 10.057

4.  Predictors for low TAVI-prosthesis position assessed by fusion imaging of pre- and post-procedural CT angiography.

Authors:  Philipp Breitbart; Gregor Pache; Jan Minners; Manuel Hein; Holger Schröfel; Franz-Josef Neumann; Philipp Ruile
Journal:  Clin Res Cardiol       Date:  2020-05-12       Impact factor: 5.460

  4 in total
  1 in total

1.  Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.

Authors:  Bruno Levy; Nicolas Girerd; Julien Amour; Emmanuel Besnier; Nicolas Nesseler; Julie Helms; Clément Delmas; Romain Sonneville; Catherine Guidon; Bertrand Rozec; Helène David; David Bougon; Oussama Chaouch; Oulehri Walid; Dupont Hervé; Nicolas Belin; Lucie Gaide-Chevronnay; Patrick Rossignol; Antoine Kimmoun; Kevin Duarte; Arthur S Slutsky; Daniel Brodie; Jean-Luc Fellahi; Alexandre Ouattara; Alain Combes
Journal:  JAMA       Date:  2022-02-01       Impact factor: 157.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.